Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 |
filingDate |
2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ae57bbe106063d2905fc8fec301ff75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_740cbf4629d7bca074acffb99454532a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91a59d3756a825ebeac1149dfe558a7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6d05c48eb009b1e8764690c119e6980 |
publicationDate |
2018-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20180045656-A |
titleOfInvention |
Pharmaceutical composition for treatment or overcoming chemo-resistance of drug resistant cancer |
abstract |
The present invention relates to a pharmaceutical composition for overcoming or treating resistance to drug-resistant bile duct cancer and / or gallbladder cancer, which comprises an anticancer agent as an active ingredient. The pharmaceutical composition of the present invention overcomes tolerance by increasing susceptibility to drugs for the treatment of cancer of resistant biliary cancer and / or gallbladder cancer cells, and further induces cell proliferation and cell death of the resistant biliary cancer and / or gallbladder cancer cells, Can be used to treat cancer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021086038-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020139044-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2801811-C1 |
priorityDate |
2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |